ClinicalTrials.gg
CompletedNCT00792688Updated Oct 28, 2021Results posted

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

A Phase 2 interventional study of GLYC-101 Gel (0.1%) and GLYC-101 Gel (1.0%) in Wounds, sponsored by TR Therapeutics. Completed at 1 site in United States. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by TR Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

02

Conditions studied

  • Wounds

Keywords

  • burn wounds
  • wound healing
03

In context

Wounds and Injuries

2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's enrollment of 26 is below the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

TR Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female healthy volunteer subjects, between 25 and 70 years of age, giving for facial laser ablation of the lower eyelid areas for the purpose of wrinkle removal.
  • Lower eyelid skin is free of any irritation, scarring or dermatologic conditions which might interfere with the study.
  • Willing and able to participate in the study and follow all study directions.
  • Able to read, understand and sign the consent form prior to any study related procedures.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test.
  • Presence of irritation or dermatologic skin conditions in the lower eyelid area.
  • Known allergies to materials within the test formulations (i.e., yeast and/or yeast products).
  • Use of topical or systemic drugs (, retinoids, immune modulators, immune suppressants, drugs with potential for contact dermatitis, drugs with potential for skin discoloration) that may have an effect on wound healing or may impact skin pigmentation.
  • A history, upon wounding, of developing thickened scars, keloids, or excessive pigment change.
  • An unstable or severe inter-current medical condition that, in the opinion of the investigator, might interfere with interpretation of study results or render the subject at high risk for treatment complications.
  • Use of any medication or device for any indication within 30 days of screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid

    Drug: GLYC-101 Gel (0.1%) · Drug: GLYC-101 Placebo

  • Experimental
    2

    GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid

    Drug: GLYC-101 Gel (1.0%) · Drug: GLYC-101 Placebo

  • Experimental
    3

    GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid

    Drug: GLYC-101 Gel (0.1%) · Drug: GLYC-101 Gel (1.0%)

Interventions

  • Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

  • Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

  • DrugGLYC-101 Placebo

    Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

06

What researchers measure

Primary outcomes

  1. Time to Complete Wound Closure (Epithelialization)

    Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject's wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.

    Time frame: Over the course of 1 month following the initial treatment.

Secondary outcomes

  1. Cosmesis/11-point Likert Scale

    The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).

    Time frame: At 1 month following the initial treatment.

07

Results

Posted Jul 25, 2011

Participant flow

Recruitment started in October 2008 and ended in 2009 at a single site, Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States, 90210.

Participant flow — Overall Study
MilestoneGLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other
Started989
Completed989
Not completed000

Outcome measures

PrimaryTime to Complete Wound Closure (Epithelialization)

Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject's wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.

Time frame:
Over the course of 1 month following the initial treatment.
Reported as:
Mean · days
Time to Complete Wound Closure (Epithelialization)
daysAll Treatments GLYC-101 Gel, 0.1%All Treatments GLYC-101 Gel, 1.0%All Treatments Placebo
Time to Complete Wound Closure (Epithelialization)10.9 ± 5.1713.1 ± 8.3116.3 ± 9.93
Statistical analysis
  • All Treatments GLYC-101 Gel, 0.1% vs All Treatments Placebo · Wilcoxon (Mann-Whitney) · p = 0.0062
  • All Treatments GLYC-101 Gel, 1.0% vs All Treatments Placebo · Wilcoxon (Mann-Whitney) · p = 0.0331
SecondaryCosmesis/11-point Likert Scale

The cosmetic effect on each lower eyelid using an 11-point Likert Scale (0 = not healed and 10 = healed).

Time frame:
At 1 month following the initial treatment.
Reported as:
Mean · scores on a scale
Cosmesis/11-point Likert Scale
scores on a scaleAll Treatments GLYC-101 Gel, 0.1%All Treatments GLYC-101 Gel, 1.0%All Treatments Placebo
Cosmesis/11-point Likert Scale8.9 ± 1.288.6 ± 1.178.5 ± 1.50

Adverse events

Collected over Adverse Events (AEs) were collected over the course of 1 month.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other Eyelid—0/9 (0%)9/9 (100%)
GLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other Eyelid—0/8 (0%)8/8 (100%)
GLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other—1/9 (11.1%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventGLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other
HIV test positiveInvestigations0/90/81/9
Most frequent other events
Most frequent other events
EventGLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the Other
Application site painGeneral disorders9/98/89/9
Procedural painInjury, poisoning and procedural complications6/95/86/9
Eye pruritusEye disorders4/93/86/9
Impaired healingGeneral disorders2/91/81/9
Chemical eye injuryInjury, poisoning and procedural complications0/91/80/9
ConjunctivitisEye disorders0/91/80/9
NauseaGastrointestinal disorders1/91/80/9
Pain in extremityMusculoskeletal and connective tissue disorders0/91/80/9
VomitingGastrointestinal disorders1/90/80/9
HeadacheNervous system disorders0/90/81/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the OtherTotal
<=18 years0000
Between 18 and 65 years97824
>=65 years0112
Age, Continuous
Age, Continuous(years)GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the OtherTotal
Mean53.1 ± 7.9846.4 ± 12.8353.3 ± 9.4151.1 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the OtherTotal
Female88622
Male1034
Region of Enrollment
Region of Enrollment(participants)GLYC-101 Gel, 0.1% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel, 1.0% on One Eyelid & Placebo on the Other EyelidGLYC-101 Gel 0.1% on 1 Eyelid & GLYC-101 Gel 1.0% on the OtherTotal
United States98926
08

Study locations

1 site
  • CLINICAL TESTING CENTER of BEVERLY HILLS
    Beverly Hills, California 90210, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2008
First posted
Nov 18, 2008
Start
Oct 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Jul 25, 2011
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00792688
Lead sponsor
TR Therapeutics
Responsible party
Sponsor
First posted
Nov 18, 2008
Start date
Oct 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Jul 25, 2011
Last update
Oct 28, 2021

Study contacts

John Joseph, MD
principal investigator · The Clinical Testing Center of Beverly Hills
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yeast .beta.-d-glucan

Start the discussion